

We use our knowledge to help our patients.

Annual Report 2008

Prague, March 1, 2009

Dear Patients, Colleagues, and Co-Workers:

2008 was a year full of results for GENNET. We opened our branch in Liberec (Reichenberg), a 1.5 million Euro project, and we succeeded in enriching our team with experienced specialists in the fields of genetics, embryology and assisted reproduction.

We passed the ISO Committee's renewal test (ISO 9001:2002). Additionally, our laboratory was the first in the Czech Republic to be certified according to ISO EN/IEC 15189:2007 standards.

In 2008, GENNET welcomed over 20,000 patients and now employs 137 staff.

Last year we invested a significant amount of money in the educational advancement of our employees and we will continue to do so this year as well.

15 years after its founding, GENNET is now among the largest clinics in the Czech Republic in the fields of genetics, prenatal diagnostics, and assisted reproduction; in the latter we have nearly doubled our cycles and welcomed patients from more than 20 countries.

*We have remained and continue to remain true to our vision and mission: „We use our knowledge to help our patients.“ Our values are summarized in two words, which we call the GENNET Code: **Commitment** and **Dedication**:*

„Commitment“ to indispensable ethical standards, high quality, science, innovation, technology, research and learning as the foundation of development. „Dedication“ – with love and respect – to our patients, co-workers, society and the environment.

On behalf of GENNET I thank all of you for a successful year and look forward to the challenges ahead!

*JUDr. Matej Stejskal
CEO, GENNET*

I. GENERAL INFORMATION

Overall, GENNET’s two clinics welcomed **20,470 patients from 15,789 families**

II. FIELD OF PRENATAL DIAGNOSTICS

Together with KlinkLab and OKB KH Liberec we achieved the following results in 1st and 2nd trimester screenings:

- 2.898 combined tests, 1st Trimester(2.5% were positive)
- 4.118 integrated tests (1st & 2nd trimesters: 3% were positive)
- 10,331 triple tests in the 2nd trimester (6% were positive)

Ultrasound Examinations

We diagnosed major hereditary defects via ultrasound in 128 cases. Overall we had:


- 4,117 ultrasound examinations in the 1st trimester
- 13,134 ultrasound examinations in the 2nd and 3rd trimesters

Overall Results of the Prenatal Diagnostics for 2008

In all, results indicated 95 chromosomal abnormalities and 126 morphological hereditary defects. Of those, 35 contained trisomy defects in chromosome 21 (Down’s syndrome). In 111 of 126 cases, the patients elected to abort the pregnancy.

The most commonly diagnosed chromosomal defects were:

Down’s Syndrome (Trisomy 21)	35
Edwards Syndrome (Trisomy 18)	10
Patau Syndrome (Trisomy 13)	2
Turner Syndrome (XO)	8
Aneuploidy	8
Triploidy	8
Total Abnormalities	95



Invasive Procedures:

- 92 CVS (23 were abnormal)
- 3.162 AMC (95 were abnormal)

All chorionic villus sampling and 2.237 (about 71%) of the amniocentesis exams were performed using a quick method of diagnosis, whereas chromosome abnormalities were predominantly diagnosed using QF- PCR techniques.

Examinations of Spontaneous Miscarriages in the 1st Trimester


In all, 217 cases were examined for the most common aneuploids (chromosomes 2, 7, 13, 14, 15, 16, 18, 21, 22, X, Y), triploids and uniparental disomy, as well as thrombophilia (Factor V Leiden) using molecular genetic techniques:

In 29% of cases a chromosomal etiology was identified; of those 16% were Trisomy 21.

In 11% of cases a possible reason for the miscarriage was a genetic mutation (such as Leiden).

Morphological defects:

Neural tube defects	6
CNS defects	11
Orofacial defects	9
Heart defects	32
Thorax defects	6
Skeleton defects	8
Digestive system defects	28
Urogenital defects	14
Limb defects	12



III. ART RESULTS – ASSISTED REPRODUCTION

In 2008 methods of assisted reproduction were indicated in 2,337 cases and there were 1,176 embryo transfers.

In 432 cycles (18%), patients were over 40 years old. In general, a large number of patients being treated were somewhat older. Nevertheless, the rate of pregnancy was satisfactory. A closer analysis of results should include information about the male factor.

Pre-implantation diagnostics were done in 40 cases. The FISH method was used primarily to diagnose chromosomal translocations.

Among the high risk cases where pre-implantation molecular diagnostics were performed were CMT 1A (Charcot Marie Tooth Disease Type 1A), cystic fibrosis, Marfan syndrome, Huntington’s disease, hemophilia and Rh incompatibility.

	IVF/ICSI	FET	ED (Jun/Dec)	PGD	IUI
Cycles	1176	244	74	40	803
Egg Withdrawals	1020		65	40	
Embryo Transfers	877	207	51	21	
Pregnancies	326	46	26	11	87
Pregnancies per Transfer (%)	37.2	22.2	51	52.4	10.8

IV. POSTNATAL LABORATORY DIAGNOSTICS

Our cytogenetic laboratory performed 2,345 examinations with 94 (4%) pathological results. The FISH Method was applied in 138 cases.

The molecular genetic laboratory examined 5,983 cases. Besides aneuploids, which were examined most often using the QF – PCR method, the following specimens were also examined:

Thrombophilic mutations (MTHFR, FVL, FII)	2.222
CF – Cystic Fibrosis	784
Y Chromosome	281
Mutations of the GJB2 gene	187
MSI	39
Nijmegen Breakage Syndrome	3
BRCA1/BRCA2	80
CMS – Congenital Myasthenic Syndrome	22
Charcot Marie Tooth Syndrome (GJB1/MPZ)	21
Spastic Paraplegia (SPG3 / SPG 4)	35
Mutations of the SOD 1 gene - Amyotrophic Lateral Sclerosis (ALS)	13

CHALLENGES FOR 2009:

2009 is an important year for GENNET.

We would like to continue to

- 1) establish our position in national and international terrain;
- 2) expand; and
- 3) invest in the most modern technologies, including:

- Chip Technology in the area of prenatal diagnostics

Innovative Technology for precise
folliculometry, SonoAVC™ follicle software

- Introduction of the IMSI method (intracytoplasmic morphologically selected sperm injection) and vitrification, including the vitrification of egg cells.

In 2009 GENNET will also continue to support several research projects around the world and be present at international conferences.

We look forward to the coming challenges and will continue to do everything in our power to live up to your expectations!

*If you would like additional information
or have press inquiries, please contact:*

*International Patient Office & Affairs (IPO)
Kostelni 9
17000 Prague 7*

*ipo@gennet.eu
+420 242 456 782*